An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to study the kinetics (study of the rate of change) of immune
recovery quality and function in stored plasma blood samples of treatment-naive (not
previously treated with antiretroviral drugs) patients with advanced human immunodeficiency
virus (HIV) infection starting a Darunavir/Ritonavir- or Efavirenz-based highly active
antiretroviral therapy (HAART) regimen.